Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration

Annals of Neurology

Volumn 75, Issue 1, 2014, Pages 116-126

  Scherling, Carole S ^a   Hall, Tracey ^b   Berisha, Flora ^b   Klepac, Kristen ^a   Karydas, Anna ^a   Coppola, Giovanni ^c   Kramer, Joel H ^a   Rabinovici, Gil ^a   Ahlijanian, Michael ^b   Miller, Bruce L ^a   Seeley, William ^a   Grinberg, Lea T ^a   Rosen, Howard ^a   Meredith, Jere ^b   Boxer, Adam L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN DEGENERATION; BRAIN SIZE; CEREBROSPINAL FLUID; CLINICAL DEMENTIA RATING; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; DISEASE SEVERITY; FEMALE; FRONTAL VARIANT FRONTOTEMPORAL DEMENTIA; FRONTOTEMPORAL DEGENERATION; GENE MUTATION; GRAY MATTER; HETEROZYGOTE; HUMAN; LIGHT CHAIN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUROFILAMENT; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; VOXEL BASED MORPHOMETRY; WHITE MATTER;

ADULT; AGED; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; FRONTOTEMPORAL LOBAR DEGENERATION; HUMANS; MALE; MIDDLE AGED; NEUROFILAMENT PROTEINS; SEVERITY OF ILLNESS INDEX;

EID: 84894071363     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24052     Document Type: Article

References (46)

1. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51: 1546-1554.
2. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology 2011; 76: 1006-1014.
3. Blennow K, Zetterberg H, Rinne JO, et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 2012; 69: 1002-1010.
4. Petersen RC,. Alzheimer's disease: progress in prediction. Lancet Neurol 2010; 9: 4-5.
5. Green AJE, Harvey RJ, Thompson EJ, Rossor MN,. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci Lett 1999; 259: 133-135.
6. Riemenschneider M, Wagenpfeil S, Diehl J, et al. Tau and A beta 42 protein in CSF of patients with frontotemporal degeneration. Neurology 2002; 58: 1622-1628.
7. Schoonenboom NSM, Pijnenburg YAL, Mulder C, et al. Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 2004; 62: 1580-1584.
8. Sjogren M, Minthon L, Davidsson P, et al. CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm 2000; 107: 563-579.
9. Bian H, Van Swieten JC, Leight S, et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 2008; 70: 1827-1835.
10. Andersen C, Froelich Fabre S, Ostberg P, et al. Tau protein in cerebrospinal fluid from semantic dementia patients. Neurosci Lett 2000; 294: 155-158.
11. Fuchs E, Cleveland DW,. A structural scaffolding of intermediate filaments in health and disease. Science 1998; 279: 514-519.
12. Rosengren LE, Karlsson JE, Karlsson JO, et al. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 1996; 67: 2013-2018.
13. Pijnenburg YAL, Janssen JC, Schoonenboom NSM, et al. CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer's disease and controls. Dement Geriatr Cogn Disord 2007; 23: 225-230.
14. Abdo WF, Bloem BR, Van Geel WJ, et al. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. Neurobiol Aging 2007; 28: 742-747.
15. Norgren N, Rosengren L, Stigbrand T,. Elevated neurofilament levels in neurological disease. Brain Res 2003; 987: 25-31.
16. Lycke JN, Karlsson JE, Andersen O, Rosengren LE,. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 64: 402-404.
17. Salzer J, Svenningsson A, Sundstrom P,. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 2010; 16: 3:287-292.
18. Tortelli R, Ruggieri M, Cortese R, et al. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol 2012; 19: 1561-1567.
19. Petzold A,. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005; 233: 183-198.
20. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
21. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP International Workshop. Neurology 1996; 47: 1-9.
22. Kang GA, Bronstein JM, Masterman DL, et al. Clinical characteristics in early Parkinson's disease in a central California population-based study. Mov Disord 2005; 20: 1133-1142.
23. Lee S, Rabinovici G, Mayo MC, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol 2011; 70: 327-340.
24. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; 72: 245-256.
25. Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006; 442: 916-919.
26. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5′ splice site mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393: 702-705.
27. Rabinovici GD, Rosen HJ, Alkalay A, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 2011; 77: 2034-2042.
28. Folstein MF, Folstein SE, McHugh PR,. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
29. Meyers JE, Meyers KR,. Rey complex figure test and recognition trial: professional manual. Lutz, FL: Psychological Assessment Resources, 1995.
30. Weshler D,. WAIS-III: Administration and Scoring Manual: San Diego, CA: Harcourt Brace & Company, 1997.
31. Kramer JH, Miller BL,. Alzheimer's disease and its focal variants. Semin Neurol 2000; 20: 447-454.
32. Delis D, Kaplan E, Kramer JH,. Delis-Kaplan executive function system (D-KEFS). San Antonio, TX: Psychological Corporation, 2001.
33. Kaplan E, Goodglass H, Weintraub S,. Boston naming test. Philadelphia, PA: Lea & Febiger, 1983.
34. Delis DC, Kramer JH, Kaplan E, Ober BA,. California verbal learning test. 2nd ed. San Antonio, TX: Psychological Corporation, 2000.
35. Morris JC,. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-2414.
36. Benjamini Y, Hochberg Y,. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995; 57: 289-300.
37. Seeley WW, Crawford R, Rascovsky K, et al. Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia. Arch Neurol 2008; 65: 249-255.
38. Sjogren M, Rosengren L, Minthon L, et al. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology 2000; 54: 1960-1964.
39. Landqvist Waldö M, Frizell Santillo A, Passant U, et al. Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia. BMC Neurol 2013; 13: 54.
40. Rosengren L, Karlsson J-E, Sjögren M, et al. Neurofilament protein levels in CSF are increased in dementia. Neurology 1999; 52: 1090.
41. Davies RR, Hodges JR, Kril JJ, et al. The pathological basis of semantic dementia. Brain 2005: 128: 9: 1984-1995.
42. Boxer AL, Mackenzie IR, Boeve BF, et al. Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. J Neurol Neurosurg Psychiatry 2011; 82: 196-203.
43. Whitwell JL, Weigand SD, Boeve BF, et al. Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain 2012; 135 (pt 3): 794-806.
44. Mechelli A, Price CJ, Friston KJ, Ashburner J,. Voxel-based morphometry of the human brain: methods and applications. Curr Med Imaging Rev 2005; 1, 1.
45. Sunderland T, Linker G, Mirza N, et al. Decreased beta-amyloid(1-42) and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003; 289: 2094-2103.
46. Boxer AL, Gold M, Huey E, et al. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimers Dement 2013; 9: 189-198.